Quality of life appears to suffer little when adding radiation to androgen deprivation for prostate cancer

Reuters Health - 06/10/2020 - Patients with low-volume metastatic prostate cancer (mPCa) receiving androgen-deprivation therapy (ADT) only temporarily experience more bowel and urinary symptoms when external beam radiotherapy (EBRT) is added to their treatment, according to new findings from the HORRAD trial. Neither treatment affected global health-related quality of life (HRQoL), "and at 24 months, no clinically relevant differences in urinary and bowel symptoms persisted," Dr. Liselotte Boeve of OLVG hospital in Amsterdam and colleagues report in European Urology. The HORRAD trial, which ran from 2004 to 2014, found improved survival for patients with primary bone mPCa who received EBRT along with ADT. Study participants completed two validated questionnaires measuring HRQoL, one specific to cancer and one to prostate cancer, at baseline and at three, six, 12 and 24 months. The authors defined a clinically significant difference as a change of 10 points or more.

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 6 October, 202022 October, 2020